Kadmon Holdings Inc. (KDMN) stock declines during pre-market trading. Here’s the update:

Kadmon Holdings Inc. (NASDAQ: KDMN) stock gained by 1.77% at last close however the KDMN stock-price plunge by 1.09% in the pre-market trading session. Kadmon is a biopharmaceutical business that develops, manufactures, and distributes novel treatments for unfulfilled medical needs.

>> 7 Top Picks for the Post-Pandemic Economy << 

KDMN stock, Current Update

REZUROCKTM (belumosudil) tablets have been included to the NCCN Clinical Practice Guidelines in Oncology for Hematopoietic Cell Transplantation in the Pre-Transplant Recipient Evaluation and Management of Graft-Versus-Host Disease, according to Kadmon Holdings (GVHD). REZUROCK is currently included as a recommended systemic treatment for steroid-refractory chronic GVHD in the NCCN Recommendations in the United States, with a Category 2A classification.

Discover Tomorrow's Stocks Today!

When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.

Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored

Read More

REZUROCK (belumosudil) 200 mg once daily (QD) was authorized by the US Food and Drug Administration on July 16, 2021, for the purpose of  treating  adult and pediatric patients 12 years and older with recurrent graft-versus-host disease (cGVHD) following failure of minimum two prior lines of systemic therapy.

Moreover,

REZUROCK was approved by the FDA due to the findings of ROCKstar (KD025-213) which is a randomized, open-label, multicenter pivotal study of REZUROCK in individuals with cGVHD who had two to five lines of systemic treatment. The NCCN recommendations state that “belumosudil is a potential treatment for steroid-refractory cGVHD that is well tolerated and yields clinically significant responses,” based on the ROCKstar trial.

The National Cancer Institute’s Cancer Centers Network is a non-profit organization comprised of 31 top cancer centers dedicated to patient safety, research, and education. NCCN is committed to developing and enabling cancer care that is effective, efficient, and accessible so that patients can live better lives.

>> 7 Top Picks for the Post-Pandemic Economy << 

Harlan W. Waksal, MD, President and CEO of KDMN Stock stated,

REZUROCK’s quick inclusion in NCCN recommendations following full FDA approval confirms the drug’s successful clinical effect in this tricky therapeutic environment. They are pleased for this significant milestone as they pursue their efforts to raise REZUROCK awareness among healthcare providers and patients with persistent GVHD.

Most Popular

Related posts